Congenital hyperinsulinism due to compound heterozygous mutations in ABCC8 responsive to diazoxide therapy

J Pediatr Endocrinol Metab. 2020 May 26;33(5):671-674. doi: 10.1515/jpem-2019-0457.

Abstract

Background Congenital hyperinsulinism (CHI), a condition characterized by dysregulation of insulin secretion from the pancreatic β cells, remains one of the most common causes of hyperinsulinemic, hypoketotic hypoglycemia in the newborn period. Mutations in ABCC8 and KCNJ11 constitute the majority of genetic forms of CHI. Case presentation A term macrosomic male baby, birth weight 4.81 kg, born to non-consanguineous parents, presented on day 1 of life with severe and persistent hypoglycemia. The biochemical investigations confirmed a diagnosis of CHI. Diazoxide was started and progressively increased to 15 mg/kg/day to maintain normoglycemia. Sequence analysis identified compound heterozygous mutations in ABCC8 c.4076C>T and c.4119+1G>A inherited from the unaffected father and mother, respectively. The mutations are reported pathogenic. The patient is currently 7 months old with a sustained response to diazoxide. Conclusions Biallelic ABCC8 mutations are known to result in severe, diffuse, diazoxide-unresponsive hypoglycemia. We report a rare patient with CHI due to compound heterozygous mutations in ABCC8 responsive to diazoxide.

Keywords: ABCC8; congenital hyperinsulinism; diazoxide.

Publication types

  • Case Reports

MeSH terms

  • Congenital Hyperinsulinism / drug therapy*
  • Congenital Hyperinsulinism / genetics*
  • Diazoxide / therapeutic use*
  • Humans
  • Infant, Newborn
  • Male
  • Sulfonylurea Receptors / genetics*
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use*

Substances

  • ABCC8 protein, human
  • Sulfonylurea Receptors
  • Vasodilator Agents
  • Diazoxide